Broadly Reactive Human CD8 T Cells that Recognize an Epitope Conserved between VZV, HSV and EBV

PLoS Pathogens

Volumn 10, Issue 3, 2014, Pages

  Chiu, Christopher ^a,b   McCausland, Megan ^a   Sidney, John ^c   Duh, Fuh Mei ^d,e   Rouphael, Nadine ^a   Mehta, Aneesh ^a   Mulligan, Mark ^a   Carrington, Mary ^d,e   Wieland, Andreas ^a   Sullivan, Nicole L ^a   Weinberg, Adriana ^f   Levin, Myron J ^f   Pulendran, Bali ^a   Peters, Bjoern ^c   Sette, Alessandro ^c   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d SAIC FREDERICK INC   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; GAMMA INTERFERON; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CD8+ T LYMPHOCYTE; CELL PROLIFERATION ASSAY; CELLULAR IMMUNITY; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; SEROLOGY; VARICELLA ZOSTER VIRUS; YOUNG ADULT;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HUMANS; SIMPLEXVIRUS; VIRAL VACCINES;

EID: 84897396291     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004008     Document Type: Article

References (31)

1. Fields BN, Knipe DM, Howley PM, editors (2007) Fields' Virology. London: Wolters Kluwer/Lippincott Williams & Wilkins. 2664 p.
2. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM, (1992) Subclinical Varicella-Zoster Virus Viremia, Herpes Zoster, and T Lymphocyte Immunity to Varicella-Zoster Viral Antigens after Bone Marrow Transplantation. J Infect Dis 165: 119-126.
3. Mehta SK, Cohrs RJ, Forghani B, Zerbe G, Gilden DH, et al. (2004) Stress-induced subclinical reactivation of varicella zoster virus in astronauts. Journal of Medical Virology 72: 174-179.
4. Papaevangelou V, Quinlivan M, Lockwood J, Papaloukas O, Sideri G, et al. (2013) Subclinical VZV reactivation in immunocompetent children hospitalized in the ICU associated with prolonged fever duration. Clin Microbiol Infect 19: E245-51.
5. Weinberg A, Levin MJ, (2010) VZV T cell-mediated immunity. Curr Top Microbiol Immunol 342: 341-357.
6. Arvin AM, (1996) Immune responses to varicella-zoster virus. Infect Dis Clin North Am 10: 529-570.
7. Good RA, Zak SJ, (1956) Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18: 109-149.
8. Patterson-Bartlett J, Levin MJ, Lang N, Schödel FP, Vessey R, et al. (2007) Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 25: 7087-7093.
9. Oxman MN, (2010) Zoster Vaccine: Current Status and Future Prospects. Clin Infect Dis 51: 197-213.
10. Diaz PS, Smith S, Hunter E, Arvin AM, (1989) T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 142: 636-641.
11. Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, et al. (1992) Immune Response of Elderly Individuals to a Live Attenuated Varicella Vaccine. J Infect Dis 166: 253-259.
12. Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR, (1994) Immune Responses Of Elderly Persons 4 Years After Receiving A Live Attenuated Varicella Vaccine. J Infect Dis 170: 522-526.
13. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, et al. (2005) A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. New England Journal of Medicine 352: 2271-2284.
14. Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, et al. (2003) Identification of CD8+ T Cell Epitopes in the Immediate Early 62 Protein (IE62) of Varicella-Zoster Virus, and Evaluation of Frequency of CD8+ T Cell Response to IE62, by Use of IE62 Peptides after Varicella Vaccination. J Infect Dis 188: 40-52.
15. Harari A, Enders FB, Cellerai C, Bart P-A, Pantaleo G, (2009) Distinct Profiles of Cytotoxic Granules in Memory CD8 T Cells Correlate with Function, Differentiation Stage, and Antigen Exposure. J Virol 83: 2862-2871.
16. Youngblood B, Wherry EJ, Ahmed R, (2011) Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. Curr Opin HIV AIDS 7: 50-57.
17. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
18. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, et al. (1989) A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173: 276-283.
19. Heineman TC, Cohen JI, (1994) Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro. Journal of Virology 68: 3317-3323.
20. Laing KJ, Dong L, Sidney J, Sette A, Koelle DM, (2012) Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clinical & Experimental Immunology 167: 47-58.
21. Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, et al. (2012) Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. Journal of Clinical Investigation 122: 654-673.
22. Posavad CM, Wald A, Hosken N, Huang ML, Koelle DM, et al. (2003) T Cell Immunity to Herpes Simplex Viruses in Seronegative Subjects: Silent Infection or Acquired Immunity? J Immunol 170: 4380-4388.
23. Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, et al. (2008) Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products. Seminars in Cancer Biology 18: 397-408.
24. Schiffer JT, Corey L, (2013) Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med 19: 280-288.
25. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, et al. (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188: 2205-2213.
26. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
27. Masopust D, Ha S-J, Vezys V, Ahmed R, (2006) Stimulation History Dictates Memory CD8 T Cell Phenotype: Implications for Prime-Boost Vaccination. J Immunol 177: 831-839.
28. Quinlivan M, Breuer J, Schmid DS, (2011) Molecular studies of the Oka varicella vaccine. Expert Review of Vaccines 10: 1321-1336.
29. Hill A, Jugovic P, York I, Russ G, Bennink J, et al. (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375: 411-415.
30. Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, et al. (2007) A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204: 1863-1873.
31. Abendroth A, Kinchington PR, Slobedman B, (2010) Varicella Zoster Virus Immune Evasion Strategies. Curr Top Microbiol Immunol 342: 155-71.